Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Industry Wants Real-World Data to Serve as Grounds for Drug Pricing: JPMA Head
March 7, 2017
- EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
- 3 Groups to Draw Up Guidelines on Inter-Pharmacy Drug Transactions by March-End
February 27, 2017
- US Exclusion from Foreign Price Adjustment Should Be Carefully Considered: PhRMA Japan Chief
February 2, 2017
- JMA Calls for Tighter Penalties on Parties Involved in Counterfeits
January 26, 2017
- JPMA Sets Up New Unit as Liaison for APAC
January 20, 2017
- NPhA Instructing Member Pharmacies on Careful Drug Purchases after Fake Harvoni Issue: Chief
January 20, 2017
- JGA Head Frets Majority of Products Subject to Gap-Year Revisions Will Be Generics
January 20, 2017
- We Must Redouble Efforts for Proper Drug Distribution, Pharmacist Group Says on Fake Harvoni Issue
January 19, 2017
- OTC Industry Group Keen on Expanding Self-Medication Tax Break: Chief
January 18, 2017
- JPMA Eager for Its Active Involvement in Drug Pricing Debates: Chief
January 18, 2017
- JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
January 18, 2017
- JGA Corrects Generic Share Data for Past 3 Years; July-Sept. Share at 65.1%
January 16, 2017
- With Annual Revisions, Drug Wholesalers Will Be Negotiating Delivery Prices All Year: JPWA Chief
January 12, 2017
- Tokyo Pharma Chief Naito Prods Govt to Secure Predictability of Pricing System
January 10, 2017
- Building Personal Relationships Will Be Crucial: FPMAJ Director General
January 6, 2017
- Annual Price Revisions Must Not Adversely Affect Distribution Environment: JPWA
December 26, 2016
- Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
December 26, 2016
- FPMAJ Accepts PMDA’s Fee Raise Plan, but Wants Tradeoff
December 16, 2016
- JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…